Investigational drug · Phase 3
Emactuzumab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cancer, TGCT.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Emactuzumab"
First trial start
2019
Feb 28, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Emactuzumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer
- TGCT
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Emactuzumab" as an intervention, largest first.
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02323191 · 221 participants · Start Jan 19, 2015 · Primary completion Aug 21, 2020
Drug: Atezolizumab; Emactuzumab · For: Solid Cancers
Sites: New Haven, Connecticut; Boston, Massachusetts; New York, New York · 12 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01494688 · 217 participants · Start Dec 20, 2011 · Primary completion Feb 7, 2018
Drug: Paclitaxel; RO5509554 · For: Advanced Solid Tumors
Sites: New York, New York; Philadelphia, Pennsylvania; Bordeaux, France · 7 sites in all
- Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)Pivotal-lookingActive, not recruiting
SynOx Therapeutics LimitedIndustry
NCT05417789 · 128 participants (planned) · Start Oct 9, 2024 · Primary completion Dec 23, 2025
Drug: Emactuzumab; Placebo · For: TGCT
Sites: Beverly Hills, California; Los Angeles, California; Columbus, Ohio · 33 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02760797 · 38 participants · Start May 9, 2016 · Primary completion Apr 6, 2018
Drug: Emactuzumab; RO7009789 · For: Neoplasms
Sites: New York, New York; Philadelphia, Pennsylvania; Brussels, Belgium · 6 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02923739 · 9 participants · Start May 5, 2017 · Primary completion Sep 27, 2022
Drug: Bevacizumab; Emactuzumab and 1 more · For: Fallopian Tube Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma and 17 more
Sites: Voorhees Township, New Jersey; Dallas, Texas; Houston, Texas · 8 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03369964 · 0 participants · Start Mar 14, 2018 · Primary completion Dec 31, 2018
Drug: Atezolizumab; Emactuzumab and 1 more · For: Lymphoma, Non-Hodgkin
Sites: Duarte, California; Nashville, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
- TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.
Gelderblom H, Palmerini E, van de Sande M, et al. · Future Oncol 2026
- Management of tenosynovial giant cell tumor: approved and investigational therapies.
Conway AP, Lim A, Schulte BC, et al. · Expert Rev Anticancer Ther 2026
- Medical Management of Tenosynovial Giant Cell Tumor.
Palmerini E, Trent JC, Hornicek FJ · Curr Oncol Rep 2025
- Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS, Katiyar V, Dy P, et al. · Hematol Oncol Stem Cell Ther 2023
- Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL · Curr Opin Oncol 2022
- Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
Lingamfelter M, Novaczyk ZB, Cheng EY · JBJS Essent Surg Tech 2022
Also in development for Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials
MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.